Innovatively protecting your IP
Creating successful and nurturing partnerships
Symbiosis IP is a patent attorney and IP commercial advisory firm that exclusively serves the life science industry.
We have a wealth of experience in working closely to provide academic institutions and early stage start-up companies with patent attorney and IP commercial advisory services. This experience enables us to develop IP that drives new businesses forward whatever their complexity. We also work with established businesses and household names to acquire and defend their IP rights.
We are committed to providing the highest quality service; to ensure this we employ attorneys and commercialisation experts with higher degrees and post-doctoral research experience across a broad range of technical disciplines in the bioscience sector. This post-doctoral research experience enables us to fully understand the technology behind your ideas and maximise the protection we can acquire for you. We also undertake continuing professional development to keep up-to-date on issues that affect our clients.
We understand that protection for IP can be expensive. We have streamlined our business to maximise efficiency and the associated cost savings are passed onto our clients via our highly-competitive charging rates. To help you plan ahead we can provide cost estimates for any stage of the patenting process with reasonable levels of reliability.
Our priority is to develop long-lasting, mutually-beneficial relationships that maximise the benefit that your technology can bring to your business.
Our senior legal team have been working in life science and chemistry for decades and so we have gained a wealth of experience and expert knowledge in many aspects of patent drafting, prosecution and enforcement in the UK, Europe and internationally. Our commercial advisory team is similarly experienced, and so can draw on an extensive knowledge of sector-specific licensing arrangements and market standards to provide robust commercial support as our clients’ IP portfolios develop.